Mosaic ImmunoEngineering (CPMV) 10-Q 2 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 02, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-22182
Entity Registrant Name	MOSAIC IMMUNOENGINEERING, INC.
Entity Central Index Key	0000836564
Entity Tax Identification Number	84-1070278
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9114 Adams Ave., #202
Entity Address, City or Town	Huntington Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92646
City Area Code	657
Local Phone Number	208-0890
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,242,137

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 252,898	$ 220,645
Prepaid expenses and other current assets	32,630	40,632
Total current assets	285,528	261,277
Total assets	285,528	261,277
Current liabilities:
Accounts payable	116,421	133,464
Derivative liability	0	46,700
Accrued compensation	2,993,793	2,399,132
Accrued consulting	809,528	753,570
Accrued expenses and other	649,225	584,808
Total current liabilities	4,568,967	3,917,674
Convertible notes, net	1,297,590	1,228,361
Total liabilities	5,866,557	5,146,035
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding	72	72
Additional paid-in capital	2,039,677	2,023,271
Accumulated deficit	(7,620,779)	(6,908,102)
Total stockholders’ deficit	(5,581,029)	(4,884,758)
Total liabilities and stockholders’ deficit	285,528	261,277
Series A Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	0	0
Series B Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	$ 1	$ 1

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Preferred Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	7,242,137	7,242,137
Common Stock, Shares, Outstanding	7,242,137	7,242,137
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized	630,000	630,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized	70,000	70,000
Preferred Stock, Shares Issued	70,000	70,000
Preferred Stock, Shares Outstanding	70,000	70,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 84,927	$ 211,082	$ 385,460	$ 841,435
General and administrative	226,944	306,124	738,690	1,288,533
Total operating expenses	311,871	517,206	1,124,150	2,129,968
Loss from operations	(311,871)	(517,206)	(1,124,150)	(2,129,968)
Other income (expense):
Gain on redemption of preferred stock of Holocom	0	343,000	433,000	343,000
Interest income	16	11	3,402	25
Change in valuation of derivative liability	0	56,700	46,700	58,000
Non-cash interest expense on convertible notes	(18,484)	(18,484)	(54,849)	(51,254)
Accretion to redemption value on convertible notes	(2,907)	(17,673)	(14,380)	(64,171)
Total other income (expense), net	(21,375)	363,554	413,873	285,600
Loss before income taxes	(333,246)	(153,652)	(710,277)	(1,844,368)
Provision for income taxes	0	0	2,400	2,400
Net loss	$ (333,246)	$ (153,652)	$ (712,677)	$ (1,846,768)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Earnings Per Share, Basic	$ (0.05)	$ (0.02)	$ (0.10)	$ (0.26)
Earnings Per Share, Diluted	$ (0.05)	$ (0.02)	$ (0.10)	$ (0.26)
Weighted Average Number of Shares Outstanding, Basic	7,236,447	7,235,447	7,236,447	7,235,447
Weighted Average Number of Shares Outstanding, Diluted	7,236,447	7,235,447	7,236,447	7,235,447

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Series A Convertible Voting Preferred Stock [Member]	Series B Convertible Voting Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 0	$ 1	$ 72	$ 1,728,148	$ (4,527,232)	$ (2,799,011)
Beginning balance, shares at Dec. 31, 2021	0	70,000	7,241,137
Share-based compensation				288,594		288,594
Net loss					(1,846,768)	(1,846,768)
Ending balance, value at Sep. 30, 2022	$ 0	$ 1	$ 72	2,016,742	(6,374,000)	(4,357,185)
Beginning balance, shares at Sep. 30, 2022	0	70,000	7,241,137
Beginning balance, value at Jun. 30, 2022	$ 0	$ 1	$ 72	1,965,150	(6,220,348)	(4,255,125)
Beginning balance, shares at Jun. 30, 2022	0	70,000	7,241,137
Share-based compensation				51,592		51,592
Net loss					(153,652)	(153,652)
Ending balance, value at Sep. 30, 2022	$ 0	$ 1	$ 72	2,016,742	(6,374,000)	(4,357,185)
Beginning balance, shares at Sep. 30, 2022	0	70,000	7,241,137
Beginning balance, value at Dec. 31, 2022	$ 0	$ 1	$ 72	2,023,271	(6,908,102)	(4,884,758)
Beginning balance, shares at Dec. 31, 2022	0	70,000
Share-based compensation				16,406		16,406
Net loss					(712,677)	(712,677)
Ending balance, value at Sep. 30, 2023	$ 0	$ 1	$ 72	2,039,677	(7,620,779)	(5,581,029)
Beginning balance, shares at Sep. 30, 2023	0	70,000	7,242,137
Beginning balance, value at Jun. 30, 2023	$ 0	$ 1	$ 72	2,034,148	(7,287,533)	(5,253,312)
Beginning balance, shares at Jun. 30, 2023	0	70,000	7,242,137
Share-based compensation				5,529		5,529
Net loss					(333,246)	(333,246)
Ending balance, value at Sep. 30, 2023	$ 0	$ 1	$ 72	$ 2,039,677	$ (7,620,779)	$ (5,581,029)
Beginning balance, shares at Sep. 30, 2023	0	70,000	7,242,137

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net loss	$ (333,246)	$ (153,652)	$ (712,677)	$ (1,846,768)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on redemption of preferred stock of Holocom	0	(343,000)	(433,000)	(343,000)
Share-based compensation			16,406	288,594
Change in fair value of derivative liability	0	(56,700)	(46,700)	(58,000)
Non-cash interest expense on convertible notes	18,484	18,484	54,849	51,254
Accretion to redemption value on convertible notes	2,907	17,673	14,380	64,171
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			8,002	(5,438)
Accounts payable			(17,043)	7,770
Accrued compensation			594,661	753,932
Accrued consulting			55,958	234,900
Accrued expenses and other			64,417	325,948
Net cash used in operating activities			(400,747)	(526,637)
Investing activities:
Proceeds from redemption of preferred stock of Holocom			433,000	343,000
Net cash provided by investing activities			433,000	343,000
Financing activities:
Proceeds from the issuance of convertible notes			0	341,632
Net cash provided by financing activities			0	341,632
Net change in cash and cash equivalents			32,253	157,995
Cash and cash equivalents, beginning of period			220,645	226,142
Cash and cash equivalents, end of period	$ 252,898	$ 384,137	252,898	384,137
Supplemental disclosure of cash flow information:
Cash paid for income taxes			2,400	2,400
Cash paid for interest			$ 0	$ 0

Organization and Business

Organization and Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	1. Organization and Business Organization Mosaic ImmunoEngineering, Inc. (the “Company,” “Mosaic,” “we,” “us,” or “our”), formerly known as Patriot Scientific Corporation, is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing our proprietary immunotherapy platform technology. Our lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as Cowpea mosaic virus (or CPMV) which is believed to be non-infectious in humans and animals. However, because of its virus structure and genetic composition, CPMV elicits a strong immune response when delivered directly into tumors as shown in our preclinical studies. Data from numerous mouse cancer models and in companion dogs with naturally occurring tumors show the ability of intratumoral (“IT”) administration of CPMV to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation. MIE-101 is currently in late-stage preclinical development and our goal is to advance MIE-101 into veterinary studies and into Phase I clinical trials within 18 to 24 months from the date we are able to raise sufficient funding. The Company has two inactive wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions Group, Inc. Going Concern and Management’s Plans The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. At September 30, 2023, the Company had cash and cash equivalents of $ 252,898 There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations and may require us to cease our operations altogether. In addition, any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. The accompanying unaudited condensed consolidated financial statements should therefore be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim period presented. Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2023, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. Recently Adopted Accounting Standards There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) during the three and nine months ended September 30, 2023, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, that the Company believes are of significance or potential significance to the Company.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	3. Fair Value of Financial Instruments The Company’s financial instruments consist of money market funds as well as an anti-dilution issuance rights liability pursuant to the License Option Agreement with Case Western Reserve University (“CWRU”) (see Note 6). The anti-dilution issuance rights met the definition of a derivative under ASC Topic 815, “Derivatives and Hedging”, and the liability was carried at fair value until the Capital Threshold (see Note 6) was met during June 2023, at which point the anti-dilutions rights were extinguished. Under this authoritative guidance, we are required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. We determine fair value based on quoted prices when available or through the use of alternative approaches, such as discounting the expected cash flows using market interest rates commensurate with the credit quality and duration of the investment or valuations by third-party professionals. The three levels of inputs that we may use to measure fair value are: · Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; · Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and · Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy at September 30, 2023 and December 31, 2022: Schedule of financial assets and liabilities Fair Value Measurements at September 30, 2023 Using Fair Value at 2023 Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 252,898 $ 252,898 $ – $ – Total assets $ 252,898 $ 252,898 $ – $ – Fair Value Measurements at December 31, 2022 Using Fair Value at Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 220,645 $ 220,645 $ – $ – Total assets $ 220,645 $ 220,645 $ – $ – Liabilities: Anti-dilution issuance rights derivative liability $ 46,700 $ – $ – $ 46,700 Total liabilities $ 46,700 $ – $ – $ 46,700 Anti-Dilution Issuance Rights Derivative Liability Pursuant to the Series B Preferred Certificate of Designation, the Series B Preferred includes certain anti-dilution issuance rights, whereby the holder will continue to maintain equity ownership equal to 10% of the fully diluted shares of common stock outstanding, calculated on an as converted basis, including all other convertible securities outstanding and reserved for issuance (and excluding stock options issued and outstanding and reserved for issuance under a Board approved employee stock option plan reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company) until we raise the Capital Threshold under the License Agreement (see Note 6). As of June 2023, we received life-to-date aggregate proceeds in excess of the Capital Threshold and therefore, we recorded no derivative liability as of September 30, 2023. As of December 31, 2022, the remaining Capital Threshold was $ 283,000 To determine the estimated fair value of the anti-dilution issuance rights liability, the Company used a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables. At December 31, 2022, the estimated fair value of the anti-dilution issuance rights was $ 46,700 The primary inputs used in valuing the anti-dilution issuance rights liability at December 31, 2022 were as follows: Schedule of assumptions used Fair value of common stock (per share) $ 0.99 Estimated additional shares of common stock 71,511 Expected volatility 130% Expected term (years) 0.25 Risk-free interest rate 4.42% The fair value of the common stock was determined by management with the assistance of an independent third-party specialist. The computation of expected volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the estimated number of shares, timing, and probability of future equity financings in the calculation of the anti-dilution issuance rights liability.

Investment in Affiliated Compan

Investment in Affiliated Companies	9 Months Ended
	Sep. 30, 2023
Investments in and Advances to Affiliates [Abstract]
Investment in Affiliated Companies	4. Investment in Affiliated Companies Holocom, Inc. In February 2007, we invested an aggregate of $ 370,000 2,100,000 46 On July 6, 2022, we entered into the Redemption Agreement with Holocom, pursuant to which we requested full redemption of our Series A Preferred Stock. Pursuant to the Redemption Agreement, we received cash proceeds in the amount of $ 336,000 840,000 Schedule of series A preferred stock to be redeemed over a period Period Shares of Series A Preferred Stock to be Redeemed each Month Monthly Redemption Proceeds to the Company Months 1-12 35,000 $14,000 Months 13-24 43,750 $17,500 Months 25-30 52,500 $21,000 We recognized the initial and monthly redemption of shares of Series A Preferred Stock using a cash basis of accounting rather than an accrual method as we were unable to assert that collection of amounts due under the redemption agreement was probable, regardless of the terms of the Redemption Agreement. Any amounts not paid within fifteen (15) days of its respective due date accrued interest at a rate of 8% per annum until fully paid and retroactively adjusted to 12% per annum from its original due date for amounts not paid within 90 days of its original due date. During the year ended December 31, 2022, of the 175,000 shares of Series A Preferred Stock to be redeemed under the aforementioned redemption schedule, Holocom redeemed 17,500 7,000 77,000 2,100,000 776,000 Schedule of exchange for aggregate net proceeds received Six Months Ended June 30, 2023 Year Ended December 31, 2022 Proceeds received $ 433,000 $ 343,000 Shares of Series A Preferred Stock redeemed 1,242,500 857,500 As of June 30, 2023, Holocom had no further obligations to us under the Redemption Agreement or any other arrangement.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	5. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: Schedule of accrued expenses September 30, 2023 December 31, 2022 Crossflo acquisition liability $ 177,244 $ 177,244 Accrued patent expenses 420,144 382,207 Other accrued expenses 51,837 25,357 Total accrued expenses and other current liabilities $ 649,225 $ 584,808 In September 2008, we acquired Patriot Data Solutions Group, Inc. (“PDSG”), formerly known as Crossflo Systems, Inc. In connection with the acquisition of Crossflo Systems, Inc., we have accrued $ 177,244

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2023
License Agreements
License Agreements	6. License Agreements License Option Agreement and License Agreement with CWRU On July 1, 2020, we signed a License Option Agreement with CWRU, granting the Company the exclusive right to license certain technology covering an immunotherapy platform technology to treat and prevent cancer in humans and for veterinary use, including MIE-101, our lead clinical candidate. Under the License Option Agreement, CWRU granted the Company the exclusive option for a period of two (2) years to negotiate and enter into a license agreement with CWRU, provided that we meet certain diligence milestones. Under the License Option Agreement, we issued CWRU 70,000 shares of Class B Common Stock at the fair market value of $7 on the date of issuance. On August 21, 2020, the Class B Stock was exchanged for shares of Series B Preferred, which included certain anti-dilution rights. Pursuant to the Certificate of Designation, the Series B Preferred holder will continue to maintain ownership equal to 10% of the fully diluted shares of common stock outstanding of the Company, including for such purposes all other convertible securities outstanding and reserved for issuance except stock options issued and outstanding and reserved for issuance under a board approved employee stock option plans reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company then outstanding, until we raise at least $1 million from the sale of either preferred, common stock, or from the net working capital acquired under the reverse merger in August 2020, or any combination thereof (“Capital Threshold”). The anti-dilution issuance rights under the License Option Agreement meet the definition of a derivative instrument under ASC Topic 815 (see Note 3). Initially, the net working capital acquired under the reverse merger in August 2020 of approximately $374,000 was applied against the Capital Threshold. Subsequent to the closing date of the reverse merger, we received additional net working capital under the reverse merger through aggregate payments received from the redemption of Holocom preferred stock (see Note 4) in the amount of $776,000 since such investment existed as of closing date of the reverse merger in August 2020 and was not included in net working capital as of the closing date. Therefore, as of June 2023, we received in excess of $1 million in net working capital under the reverse merger and have met the Capital Threshold. As such, there is no On May 4, 2022, we exercised our rights under the License Option Agreement and entered into a license agreement with CWRU (“License Agreement”). Pursuant to the terms of the License Agreement, we agreed to pay CWRU for each licensed product used in human applications (i) development milestones of up to $1.8 million in aggregate dependent upon the progress of clinical trials, regulatory approvals, and initiation of product launch, (ii) tiered royalty on net sales beginning in the mid-single digits, (iii) annual minimum royalty of $10,000 beginning on the second anniversary date of the Agreement with the minimum amount rising based on net sales of the licensed product, and (iv) a declining percentage of all non-royalty sublicensing income based on the escalating stage of development upon a sublicensing event, if applicable. In addition, we agreed to pay CWRU for each licensed product used in veterinarian applications (i) a tiered royalty on net sales beginning in the low single digits and (ii) a declining percentage of all non-royalty sublicensing income based on the escalating stage of development upon a sublicensing event, if applicable. In addition, we are responsible for the reimbursement of all past, current and future patent fees incurred by CWRU under the License Agreement. During the three and nine months ended September 30, 2023, we incurred $ 5,559 31,737 17,549 299,361 Furthermore, we agreed to reimburse CWRU for all intellectual property fees incurred since inception of the portfolio through the date of the License Agreement in the amount of approximately $ 303,000 (included in Accrued expenses and other in the accompanying condensed consolidated balance sheets) in four (4) equal quarterly installments beginning upon the sooner of (i) August 31, 2021 or (ii) upon the Company closing a financing in the amount of $5 million or more. Due to our limited cash position, as of September 30, 2023, we have not paid any amounts owed to CWRU and we continue to seek additional time to raise sufficient capital in order to pay amounts due to CWRU. While CWRU has previously provided us additional time to pay amounts due under the License Agreement beyond the initial August 31, 2021 due date, there can be no guarantees that CWRU will grant us any additional extension of time to pay amounts due under the License Agreement. If we fail to comply with our obligations under the License Agreement, including the payment of all amounts due under the License Agreement, we may lose the rights to develop and potentially commercialize our technology, and CWRU may have the right to terminate the License Agreement or restrict our rights, in which event we would not be able to develop or market products covered by the License Agreement, which are the products upon which our business depends. As of September 30, 2023 and December 31, 2022, we have accrued $ 396,244 and $ 364,507 , respectively, in accrued patent fees under the License Agreement. The License Agreement will remain in effect until the later of (i) twenty (20) years from the date of the License Agreement, (ii) on the expiration date of the last-to-expire patent under the License Agreement or (iii) at the expiry of all Market Exclusivity Periods for a licensed product. License Agreements with University of California San Diego (“UC San Diego”) During July 2021, we licensed the exclusive rights from UC San Diego to develop and commercialize technology that involves the loading of immuno-stimulatory molecules into plant virus protein nanoparticles, including the ability to load these molecules into MIE-101, our lead product candidate. These plant virus protein nanoparticles can be loaded with other TLR agonists to further tailor specific immune response parameters. Under the licensing agreement, we are obligated to pay (i) a nominal upfront license access fee, (ii) all patent costs incurred prior to the effective date of the license agreement, (iii) annual license maintenance fees beginning on the second anniversary date of the agreement, (iv) aggregate future milestone payments based on potential clinical development and regulatory milestones of up to $ 165,000 During September 2021, we licensed the exclusive rights to develop and commercialize several novel vaccine candidates, including SARS-CoV-2 and other infectious disease applications from UC San Diego. Under the licensing agreement, we are obligated to pay (i) a nominal upfront license access fee, (ii) all patent costs incurred prior to the effective date of the license agreement, (iii) annual license maintenance fees beginning on the second anniversary date of the agreement, (iv) aggregate future milestone payments based on potential clinical development and regulatory milestones of up to $1,250,000 through Phase III development plus additional milestones upon regulatory approval in the U.S. and other countries, and (v) a low single digit royalty on net sales and/or a percentage of sublicense income. On July 12, 2023, we provided notice to UC San Diego to terminate the September 2021 license agreement based on our evaluation of our licensed technology portfolio and our focus on advancing our lead oncology candidate, MIE-101. For the three and nine months ended September 30, 2023, we expensed $ 6,000 6,200 400 23,325 23,900 17,700

Convertible Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Convertible Notes	7. Convertible Notes On May 7, 2021, we entered into a convertible note purchase agreement (“May Note Agreement”) with five (5) accredited investors, including three (3) members of our Board of Directors (“Board”) that participated on the same terms as other accredited investors. Pursuant to the Note Agreement, we received $ 525,003 49,997 575,000 On February 18, 2022, we entered into additional convertible note purchase agreements (“February Note Agreement”) with sixteen (16) accredited investors, including five (5) members of our Board that participated on the same terms as other accredited investors. Pursuant to the February Note Agreement, we received $ 341,632 341,632 The May and February Convertible Notes (collectively, the “Convertible Notes”) have no stated maturity date; bear interest at a simple rate equal to eight percent ( 8.0 18,484 54,849 18,484 51,254 The Convertible Notes will convert into the same equity securities offered in the Qualified Financing or Smaller Financing (“Conversion Shares”), as described below, at a conversion price equal to the lower of (i) the product equal to 80% times the lowest per unit purchase price of the equity securities issued for cash in the Qualified Financing or Smaller Financing, or (ii) $2.377 for the May Convertible Notes (“May Conversion Price”) or $1.00 for the February Convertible Notes (“February Conversion Price”). Pursuant to the February Note Agreement, for each holder of the May Convertible Notes that purchased a February Convertible Note in the amount of (a) $50,000 or (b) an amount equivalent to the principal amount of their May Convertible Note, the conversion price of the May Convertible Notes was adjusted to the February Conversion Price. As of September 30, 2023, the principal amount of Convertible Notes that may be converted at the February Conversion Price was $866,632. In addition, the conversion price may be reduced or increased proportionately as a result of stock splits, stock dividends, recapitalizations, reorganizations, and similar transactions. Upon any conversion of the Convertible Notes in connection with a Qualified Financing or a Smaller Financing, as applicable, the Convertible Notes shall convert immediately prior to the closing thereof, such that the investors paying cash in such Qualified Financing or Smaller Financing, as applicable, are not diluted by the conversion of the Convertible Notes. Pursuant to the Convertible Notes, a Qualified Financing represents a single transaction or series of transactions whereby the Company receives aggregate gross proceeds of at least $5 million from the sale of equity securities following the issuance date (excluding proceeds from the issuance of any future convertible notes). A Smaller Financing represents any sale of equity securities whereby the aggregate gross proceeds are less than $5 million (excluding proceeds from the issuance of any future convertible notes). In addition, in the event of a corporate transaction covering the sale of all or substantially all of the Company’s assets, or merger or consolidation with or into another entity, or change in ownership of at least 50% in voting securities of the Company, the holder of the Convertible Note may elect that either: (a) the Company pay the holder of such Convertible Note an amount equal to the sum of (i) all accrued and unpaid interest due on such Convertible Note and (ii) one and one-half (1.5) times the outstanding principal balance of such Convertible Note; or (b) such Convertible Note will convert into that number of conversion shares equal to the quotient obtained by dividing (i) the outstanding principal balance and unpaid accrued interest of such Convertible Note on the date of conversion by (ii) the May or February Conversion Price, as applicable. Pursuant to ASC Topic 835-30, “Imputation of Interest”, the Convertible Notes were initially recorded at their amortized cost of $916,632 and are being accreted to their redemption value of $ 1,145,790 2,907 14,380 17,673 64,171

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) and Share-Based Compensation	9 Months Ended
	Sep. 30, 2023
Stockholders Equity Deficit And Share-based Compensation
Stockholders’ Equity (Deficit) and Share-Based Compensation	8. Stockholders’ Equity (Deficit) and Share-Based Compensation Stockholders’ Equity (Deficit) The Company’s authorized capital consists of 100,000,000 shares of common stock, par value $0.00001 per share, and 5,000,000 shares of preferred stock, par value $0.00001 per share (“Preferred Stock”). We have designated and issued 630,000 shares of Series A Convertible Voting Preferred Stock (“Series A Preferred”) and 70,000 shares of Series B Convertible Voting Preferred Stock (“Series B Preferred”). As of September 30, 2023 and December 31, 2022, there are no 70,000 Series B Preferred On August 21, 2020, the Company issued 70,000 shares of Series B Preferred (classified as permanent equity), in exchange for 70,000 shares of Class B Common Stock in connection with the reverse merger in August 2020. Each share of Series B Preferred has a par value of $0.00001 per share, no dividend rate, a stated value of $6.50 per share, and each share of Series B Preferred initially converts into 11.46837 shares of common stock of the Company (“Series B Conversion Number”). In addition, the Series B Preferred possesses full voting rights, on an as-converted basis, as the common stock of the Company, as defined in the Series B Certificate of Designation. Furthermore, the Series B Preferred does not have any mandatory conversion rights and only converts upon written notice from the holder. The Series B Preferred also includes certain anti-dilution rights (“anti-dilution issuance rights”), whereby the holder of Series B Preferred will continue to maintain ownership equal to 10% of the fully diluted shares of common stock outstanding, including for such purposes all other convertible securities outstanding and reserved for issuance except equity awards issued and outstanding and reserved for issuance under a board approved equity compensation plan reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company then outstanding, until the Capital Threshold is met. The anti-dilution issuance rights meet the definition of a derivative instrument under FASB’s ASC Topic 815 (see Note 3). As of June 2023, the $1 million dollar Capital Threshold was achieved and therefore, there is no remaining derivative liability (see Note 6). In the event of any Liquidation Event, the Holders of Series B Preferred shall be entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of common stock, an amount per share in cash equal to the greater of (x) the stated value of $6.50 for each share of Series B Preferred then held by the holder or (y) the amount payable per share of common stock which such holder of Series B Preferred would have received if such Holder had converted to common stock immediately prior to the Liquidation Event. Share-Based Compensation 2020 Omnibus Incentive Plan On October 21, 2020, we adopted our 2020 Omnibus Incentive Plan (the “2020 Plan”) and on October 22, 2020, the 2020 Plan was approved by our stockholders. The 2020 Plan was adopted to promote our long-term success and the creation of stockholder value by motivating participants, through equity incentive awards, to achieve long-term success in our business. The 2020 Plan permits the discretionary award of stock options, restricted stock, RSUs, and other equity awards to selected participants. On October 21, 2021, the first anniversary date from the adoption date of the 2020 Plan, the number of shares of common stock reserved for issuance under the 2020 Plan increased to 20% of the fully diluted shares of common stock outstanding, including shares of common stock reserved for issuance under convertible securities. As of September 30, 2023, we have reserved 1,661,966 541,957 1,105,965 The cost of all share-based awards will be recognized in the consolidated financial statements based on the fair value of the awards. The fair value of stock option awards will be determined using the Black-Scholes valuation model on the date of grant. The fair value of restricted stock awards and RSUs will be equal to the closing market price of our common stock on the date of grant. The Company will generally recognize share-based compensation expense over the period of vesting or period that services will be provided for all time-based awards. Share-based compensation expense for the three and nine months ended September 30, 2023 and 2022 was comprised of the following: Schedule of share-based compensation Three Months Ended Nine Months Ended September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Research and development $ 5,529 $ 15,579 $ 16,406 $ 117,123 General and administrative – 36,013 – 171,471 Total $ 5,529 $ 51,592 $ 16,406 $ 288,594 The following summarizes our transaction activity related to RSUs for the nine months ended September 30, 2023: Shares Weighted Average Grant Date Fair Value Nonvested and outstanding at January 1, 2023 541,957 $ 3.01 Granted – – Vested – – Forfeited – – Nonvested and outstanding at September 30, 2023 541,957 $ 3.01 As of September 30, 2023, the total estimated unrecognized compensation cost related to non-vested RSUs was approximately $ 10,000 0.47 14,044

Basic and Diluted Income (Loss)

Basic and Diluted Income (Loss) Per Common Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Basic and Diluted Income (Loss) Per Common Share	9. Basic and Diluted Income (Loss) Per Common Share Basic income (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is computed by dividing our net income (loss) available to common stockholders by the sum of the weighted average number of common shares outstanding during the period, plus the potential dilutive effects of unvested RSUs and shares of common stock expected to be issued under our Convertible Notes and Series B Preferred during the period. The potential dilutive effect of unvested RSUs outstanding during the period are calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. The potential dilutive effect of our Convertible Notes and Series B Preferred outstanding during the period is calculated using the if-converted method assuming the conversion of Convertible Notes and Series B Preferred as of the earliest period reported or at the date of issuance, if later, but are excluded if their effect is anti-dilutive. For the three and nine months ended September 30, 2023 and 2022, weighted average diluted shares outstanding exclude the dilutive effect of unvested RSUs and shares of common stock expected to be issued under our Convertible Notes and Series B Preferred as the effect of their inclusion would have been anti-dilutive during periods of net loss.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Legal Matters While the Company is not involved in any litigation as of September 30, 2023, the Company may be involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. Any litigation could have a material adverse effect on the Company’s business, financial condition, results of operations, and/or cash flows in the period in which the unfavorable outcome occurs or becomes probable, and potentially in future periods. Indemnification We have made certain guarantees and indemnities, under which we may be required to make payments to a guaranteed or indemnified party. We indemnify our directors, officers, employees, and agents to the maximum extent permitted under the laws of the State of Delaware. The duration of the guarantees and indemnities varies, and in many cases is indefinite. These guarantees and indemnities do not provide for any limitation of the maximum potential future payments we could be obligated to make. Historically, we have not been obligated to make any payments for these obligations and no liabilities have been recorded for these guarantees and indemnities in the accompanying unaudited condensed consolidated balance sheets. Escrow Shares On August 31, 2009, we gave notice to the former shareholders of Crossflo and Union Bank of California (the “Escrow Agent”) under Section 2.5 of the Agreement and Plan of Merger between us and Crossflo (the “Agreement”), outlining damages incurred by us in conjunction with the acquisition of Crossflo, and seeking the return of 5,690 shares of our common stock held by the Escrow Agent. Subsequently, former shareholders of Crossflo, representing a majority of the escrowed shares responded in protest to our claim, delaying the release of the escrowed shares until a formal resolution is reached. In the event we fail to prevail in our claim against the escrowed shares, we may be obligated to deposit into escrow approximately $256,000 of cash consideration due to the decline in our average stock price over the one-year escrow period calculated in accordance with the agreement. We have evaluated the potential for loss regarding our claim and believe that it is probable that the resolution of this issue will not result in a material obligation to the Company, although there is no assurance of this. Accordingly, we have not recorded any liability for this matter. Operating Lease We have no lease obligations as of September 30, 2023 and there was no

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Parties	11. Related Parties During April 2021, we entered into consulting agreements (retroactive to September 1, 2020) with Nicole Steinmetz, Ph.D., former acting Chief Scientific Officer and former member of the Board of Directors, Jonathan Pokorski, Ph.D. (Dr. Steinmetz’s spouse), and Steve Fiering, Ph.D., each a co-founder of the company acquired in the reverse merger and greater than 5% shareholder of the Company (“Related Parties”), for their scientific contributions towards advancing the technology platforms. On May 2, 2023, Dr. Steinmetz resigned from the Board of Directors and her role as acting Chief Scientific Officer. During the three months ended September 30, 2023, we did not incur any related party consulting expenses for Dr. Steinmetz or Dr. Pokorski. During the three months ended September 30, 2023, we incurred related party consulting expenses for Dr. Fiering in the aggregate amount of $ 7,500 286,375 238,000 In addition, on May 7, 2021, we entered into convertible note purchase agreements with five (5) accredited investors, including three (3) members of our Board of Directors that participated on the same terms as other accredited investors, in the aggregate principal amount of $575,000. Of such amount, the three members of our Board of Directors invested $225,000 in aggregate (see Note 7). Moreover, on February 18, 2022, we entered into convertible note purchase agreements with sixteen (16) accredited investors, including five (5) members of our Board that participated on the same terms as other accredited investors, in the aggregate principal amount of $341,632. Of such amount, the five (5) members of our Board invested $155,000 in aggregate (see Note 7).

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events We have evaluated subsequent events after the consolidated balance sheet date and through the filing date of this Quarterly Report, and based on our evaluation, management has determined that no subsequent events have occurred that would require recognition in the accompanying unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed herein and in the accompanying notes.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America. The accompanying unaudited condensed consolidated financial statements should therefore be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. In the opinion of management, the interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the results for the interim period presented.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies during the three and nine months ended September 30, 2023, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards There have been no new accounting pronouncements adopted by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”) during the three and nine months ended September 30, 2023, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, that the Company believes are of significance or potential significance to the Company.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities	Schedule of financial assets and liabilities Fair Value Measurements at September 30, 2023 Using Fair Value at 2023 Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 252,898 $ 252,898 $ – $ – Total assets $ 252,898 $ 252,898 $ – $ – Fair Value Measurements at December 31, 2022 Using Fair Value at Quoted Prices Significant Other Significant Assets: Cash and cash equivalents $ 220,645 $ 220,645 $ – $ – Total assets $ 220,645 $ 220,645 $ – $ – Liabilities: Anti-dilution issuance rights derivative liability $ 46,700 $ – $ – $ 46,700 Total liabilities $ 46,700 $ – $ – $ 46,700 Anti-Dilution Issuance Rights Derivative Liability Pursuant to the Series B Preferred Certificate of Designation, the Series B Preferred includes certain anti-dilution issuance rights, whereby the holder will continue to maintain equity ownership equal to 10% of the fully diluted shares of common stock outstanding, calculated on an as converted basis, including all other convertible securities outstanding and reserved for issuance (and excluding stock options issued and outstanding and reserved for issuance under a Board approved employee stock option plan reserving for issuance no more than ten percent (10%) of the outstanding common stock of the Company) until we raise the Capital Threshold under the License Agreement (see Note 6). As of June 2023, we received life-to-date aggregate proceeds in excess of the Capital Threshold and therefore, we recorded no derivative liability as of September 30, 2023. As of December 31, 2022, the remaining Capital Threshold was $ 283,000 To determine the estimated fair value of the anti-dilution issuance rights liability, the Company used a Monte Carlo simulation methodology, which models the future movement of stock prices based on several key variables. At December 31, 2022, the estimated fair value of the anti-dilution issuance rights was $ 46,700 The primary inputs used in valuing the anti-dilution issuance rights liability at December 31, 2022 were as follows:
Schedule of assumptions used	Schedule of assumptions used Fair value of common stock (per share) $ 0.99 Estimated additional shares of common stock 71,511 Expected volatility 130% Expected term (years) 0.25 Risk-free interest rate 4.42%

Investment in Affiliated Comp_2

Investment in Affiliated Companies (Tables)	9 Months Ended
	Sep. 30, 2023
Investments in and Advances to Affiliates [Abstract]
Schedule of series A preferred stock to be redeemed over a period	Schedule of series A preferred stock to be redeemed over a period Period Shares of Series A Preferred Stock to be Redeemed each Month Monthly Redemption Proceeds to the Company Months 1-12 35,000 $14,000 Months 13-24 43,750 $17,500 Months 25-30 52,500 $21,000
Schedule of exchange for aggregate net proceeds received	Schedule of exchange for aggregate net proceeds received Six Months Ended June 30, 2023 Year Ended December 31, 2022 Proceeds received $ 433,000 $ 343,000 Shares of Series A Preferred Stock redeemed 1,242,500 857,500

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of accrued expenses	Schedule of accrued expenses September 30, 2023 December 31, 2022 Crossflo acquisition liability $ 177,244 $ 177,244 Accrued patent expenses 420,144 382,207 Other accrued expenses 51,837 25,357 Total accrued expenses and other current liabilities $ 649,225 $ 584,808

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) and Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders Equity Deficit And Share-based Compensation
Schedule of share-based compensation	Schedule of share-based compensation Three Months Ended Nine Months Ended September 30, 2023 September 30, 2022 September 30, 2023 September 30, 2022 Research and development $ 5,529 $ 15,579 $ 16,406 $ 117,123 General and administrative – 36,013 – 171,471 Total $ 5,529 $ 51,592 $ 16,406 $ 288,594
Stockholders' Equity and Share-Based Compensation (Details - RSU activity)	Shares Weighted Average Grant Date Fair Value Nonvested and outstanding at January 1, 2023 541,957 $ 3.01 Granted – – Vested – – Forfeited – – Nonvested and outstanding at September 30, 2023 541,957 $ 3.01

Organization and Business (Deta

Organization and Business (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 252,898	$ 220,645

xdx_ Disclosure - Fair Value of

xdx: Disclosure - Fair Value of Financial Instruments (Details - Fair Value) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	$ 252,898	$ 220,645
Fair value of liabilities		46,700
Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	252,898	220,645
Fair value of liabilities		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	0	0
Fair value of liabilities		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	0	0
Fair value of liabilities		46,700
Cash [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	252,898	220,645
Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	252,898	220,645
Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets		0
Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of assets	$ 0	0
Antidilution Issuance Rights Liability [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities		46,700
Antidilution Issuance Rights Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities		0
Antidilution Issuance Rights Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities		0
Antidilution Issuance Rights Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of liabilities		$ 46,700

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details - Assumption) - Antidilution Issuance Rights Liability [Member]	12 Months Ended
	Dec. 31, 2022
Measurement Input, Share Price [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivatives, Determination of Fair Value	0.99
Additional Shares Of Common Stock [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivatives, Determination of Fair Value	71,511
Measurement Input, Price Volatility [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivatives, Determination of Fair Value	130%
Measurement Input, Expected Term [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivatives, Determination of Fair Value	0.25
Measurement Input, Risk Free Interest Rate [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivatives, Determination of Fair Value	4.42%

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Details Narrative) - USD ($)	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Offsetting Assets [Line Items]
Derivative liability	$ 0	$ 0	$ 46,700
License Option Agreement [Member]
Offsetting Assets [Line Items]
Capital threshold remaining			$ 283,000

Investment in Affiliated Comp_3

Investment in Affiliated Companies (Details - Redemption Schedule) - Holocom Series A Preferred Stock [Member]	Sep. 30, 2023 USD ($) shares
Months 1 To 12 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Investment shares to be redeemed, shares | shares	35,000
Investment shares to be redeemed, value | $	$ 14,000
Months 13 To 24 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Investment shares to be redeemed, shares | shares	43,750
Investment shares to be redeemed, value | $	$ 17,500
Months 25 To 30 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Investment shares to be redeemed, shares | shares	52,500
Investment shares to be redeemed, value | $	$ 21,000

Investment in Affiliated Comp_4

Investment in Affiliated Companies (Details - Aggregate Net Proceeds) - Series A Preferred Stock [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Proceeds received	$ 433,000	$ 343,000
Shares of Series A Preferred Stock redeemed	1,242,500	857,500

Investment in Affiliated Comp_5

Investment in Affiliated Companies (Details Narrative) - Holocom Inc [Member] - USD ($)		1 Months Ended		3 Months Ended	12 Months Ended
	Jul. 06, 2022	Dec. 31, 2022	Feb. 28, 2007	Mar. 31, 2023	Jun. 30, 2023
Investments			$ 370,000
Investment shares owned			2,100,000
Ownership interest in Holocom			46%
Proceeds from Sale of Long-Term Investments	$ 336,000	$ 7,000		$ 77,000	$ 776,000
Investment owned, shares redeemed	840,000	17,500			2,100,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Crossflo acquisition liability	$ 177,244	$ 177,244
Accrued patent expenses	420,144	382,207
Other accrued expenses	51,837	25,357
Total accrued expenses and other current liabilities	$ 649,225	$ 584,808

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities (Details Narrative)	Sep. 30, 2023 USD ($)
Crossflo Investors [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Possible Accounts Payable	$ 177,244

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Dec. 31, 2022
Derivative liability	$ 0		$ 0		$ 0	$ 46,700
General and administrative expense	226,944	$ 306,124	738,690	$ 1,288,533
U C San Diego [Member]
Regulatory milestones			165,000
General and administrative expense	6,000	400	6,200	23,325
License Option Agreement [Member] | C W R U [Member]
Accrued patent fees	396,244		396,244			364,507
License Agreements [Member] | U C San Diego [Member]
Accrued patent fees	23,900		23,900			$ 17,700
General and Administrative Expense [Member] | License Option Agreement [Member]
Patent legal fees	5,559	$ 17,549	31,737	$ 299,361
[custom:AccruedPatentCosts-0]	$ 303,000		$ 303,000

Convertible Notes (Details Narr

Convertible Notes (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended
	Feb. 18, 2022	May 07, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Proceeds from Convertible Debt					$ 0	$ 341,632
Non-cash interest expense on Convertible Notes			$ 18,484	$ 18,484	54,849	51,254
Redemption value			1,145,790		1,145,790
Accretion to Redemption Value			2,907	17,673	$ 14,380	64,171
May Note Agreement [Member]
Debt Instrument [Line Items]
Proceeds from Convertible Debt		$ 525,003
Accrued payable		49,997
Principal amount		$ 575,000
February Note Agreement [Member]
Debt Instrument [Line Items]
Proceeds from issuance of unsecured debt	$ 341,632
Convertible Notes Payable	$ 341,632
Convertible Notes [Member]
Debt Instrument [Line Items]
Interest					8%
Non-cash interest expense on Convertible Notes			18,484	18,484	$ 54,849	51,254
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Accretion to Redemption Value			$ 2,907	$ 17,673	$ 14,380	$ 64,171

Stockholders Equity (Deficit) a

Stockholders Equity (Deficit) and Share-Based Compensation (Details - Share-Based Compensation expense) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total	$ 5,529	$ 51,592	$ 16,406	$ 288,594
Research and Development Expense [Member]
Total	5,529	15,579	16,406	117,123
General and Administrative Expense [Member]
Total	$ 0	$ 36,013	$ 0	$ 171,471

Stockholders' Equity and Share-

Stockholders' Equity and Share-Based Compensation (Details - RSU activity) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
RSU's outstanding | shares	541,957
RSU's outstanding, weighted average price | $ / shares	$ 3.01
RSU's granted | shares	0
RSU's granted, weighted average price | $ / shares	$ 0
RSU's vested | shares	0
RSU's vested, weighted average price | $ / shares	$ 0
RSU's forfeited | shares	0
RSU's forfeited, weighted average price | $ / shares	$ 0
RSU's outstanding | shares	541,957
RSU's outstanding, weighted average price | $ / shares	$ 3.01

Stockholders_ Equity (Deficit_3

Stockholders’ Equity (Deficit) and Share-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 10,000
Remaining weighted average vesting period	5 months 19 days
RSU's vested	0
2020 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock for reserved for Issuance	1,661,966
2020 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock for reserved for Issuance	541,957
RSU's vested	14,044
2020 Plan [Member] | Share Based Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock for reserved for Issuance	1,105,965
Series A Preferred Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Preferred stock, shares outstanding	0	0
Series B Preferred Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Preferred stock, shares outstanding	70,000	70,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Operating Lease, Expense	$ 0	$ 0	$ 0	$ 0

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
[custom:AccruedConsulting-0]	$ 809,528	$ 753,570
Dr Fiering [Member] | Research and Development Expense [Member]
Related Party Transaction [Line Items]
Professional and Contract Services Expense	7,500
Related Parties [Member]
Related Party Transaction [Line Items]
[custom:AccruedConsulting-0]	$ 286,375	$ 238,000